How many people do you think die from snake bites? A few hundred? Incredibly it is 11,000 a month, or about 138,000 a year.
Toxic bites by wild animals are still a major public health problem for emerging markets led by India, which suffers about half of all snake bite deaths each year.1 A further half a million people worldwide are severely injured, often leading to amputation of infected limbs.
And snakes are far from being the biggest killer. The world’s most deadly creature is not humans causing wars or famine, as many people think, but the mosquito. Malaria caused by mosquito bites killed 720,000 people in 2016, ranking far above terrorism (34,000) or conflicts (116,000).2
The scale of death rates from animals in emerging markets is surprising to people in the west, for whom snakes only reside in zoos and a few pet cages. However, it also offers an opportunity for investors to support the United Nations’ Sustainable Development Goals (SDGs), some of which strive to eradicate these problems.
Treatments for injuries such as snake bites, malaria and other animal-borne diseases such as rabies are not widely available, and are often not affordable. There is a global shortage of snake venom antidotes, and drugs to prevent malaria from mosquito bites are usually a luxury that only western tourists can afford.
Subsequently, the SDGs aim to channel investment into projects that can lead to enhancement. SDG 3, for example, has a goal of promoting good health and well-being, including the availability of medicines in emerging markets. Some investors are now launching funds to invest in those companies that can directly contribute to the SDGs.
“The SDGs function as a taxonomy for investors to categorize the impact that companies have on society,” says Guido Moret, Robeco’s Head of Sustainability Integration Credits. “At Robeco and RobecoSAM, we have developed a methodology to assess this impact, based on what companies produce, how their business is run, and if any controversies are known. Next to the positive impact, we also look at the potential negative contribution of a company on the SDGs. If a company does have a negative impact, it is no longer eligible for our SDG credit funds.”
“To illustrate this, let’s look at the pharmaceutical industry. As a baseline, pharmaceutical companies have a positive impact on SDG 3 – good health and well-being. However, in our analysis, we also look for instance at the percentage of business in emerging markets, and the pricing strategy of pharmaceutical firms. After this assessment, only the pharmaceutical companies that pass the bar of positive contribution remain eligible for investment.”
The Robeco Capital Growth Funds have not been registered under the United States Investment Company Act of 1940, as amended, nor or the United States Securities Act of 1933, as amended. None of the shares may be offered or sold, directly or indirectly in the United States or to any U.S. Person (within the meaning of Regulation S promulgated under the Securities Act of 1933, as amended (the “Securities Act”)). Furthermore, Robeco Institutional Asset Management B.V. (Robeco) does not provide investment advisory services, or hold itself out as providing investment advisory services, in the United States or to any U.S. Person (within the meaning of Regulation S promulgated under the Securities Act).
This website is intended for use only by non-U.S. Persons outside of the United States (within the meaning of Regulation S promulgated under the Securities Act who are professional investors, or professional fiduciaries representing such non-U.S. Person investors. By clicking “I Agree” on our website disclaimer and accessing the information on this website, including any subdomain thereof, you are certifying and agreeing to the following: (i) you have read, understood and agree to this disclaimer, (ii) you have informed yourself of any applicable legal restrictions and represent that by accessing the information contained on this website, you are not in violation of, and will not be causing Robeco or any of its affiliated entities or issuers to violate, any applicable laws and, as a result, you are legally authorized to access such information on behalf of yourself and any underlying investment advisory client, (iii) you understand and acknowledge that certain information presented herein relates to securities that have not been registered under the Securities Act, and may be offered or sold only outside the United States and only to, or for the account or benefit of, non-U.S. Persons (within the meaning of Regulation S under the Securities Act), (iv) you are, or are a discretionary investment adviser representing, a non-U.S. Person (within the meaning of Regulation S under the Securities Act) located outside of the United States and (v) you are, or are a discretionary investment adviser representing, a professional non-retail investor. Access to this website has been limited so that it shall not constitute directed selling efforts (as defined in Regulation S under the Securities Act) in the United States and so that it shall not be deemed to constitute Robeco holding itself out generally to the public in the U.S. as an investment adviser. Nothing contained herein constitutes an offer to sell securities or solicitation of an offer to purchase any securities in any jurisdiction. We reserve the right to deny access to any visitor, including, but not limited to, those visitors with IP addresses residing in the United States.
This website has been carefully prepared by Robeco. The information contained in this publication is based upon sources of information believed to be reliable. Robeco is not answerable for the accuracy or completeness of the facts, opinions, expectations and results referred to therein. Whilst every care has been taken in the preparation of this website, we do not accept any responsibility for damage of any kind resulting from incorrect or incomplete information. This website is subject to change without notice. The value of the investments may fluctuate. Past performance is no guarantee of future results. If the currency in which the past performance is displayed differs from the currency of the country in which you reside, then you should be aware that due to exchange rate fluctuations the performance shown may increase or decrease if converted into your local currency. For investment professional use only. Not for use by the general public.